Several Years Ago,Your Generosity Helped Put A Dream Team Of Scientists Together In Calgary To Tackle Glioblastoma, One Of The Most Difficult Cancers To Treat

Glioblastoma main image

That investment continues to pay off as researchers out of the University of Calgary led by Dr. Gregory Cairncross, the Alberta Cancer Foundation Chair in Brain Cancer Research, have made a discovery that could change the standard of care for glioblastoma patients in Alberta, and across the globe.

Glioblastoma is the most common and deadly form of brain cancer among adults. The progression and complexity of the tumours are often difficult to treat and the median survival for patients is 15 months, with less than five per cent of patients surviving beyond five years. Scientists at the University of Calgary’s Hotchkiss Brain Institute (HBI) and Southern Alberta Cancer Research Institute (SACRI) used human brain tumour-initiating cells from 100 glioblastoma patients to test a drug that could target the disease. Researchers found that when the drug, AZD8055, was combined with Temozolomide (TMZ), a drug already taken by most glioblastoma patients, it could extend the life of patients by 30 percent.

“Shutting off vital tumour growth processes can lead to the death of human brain tumour-initiating cells. Our research has identified a key process in brain tumour growth that we were able to target with AZD8055,” says Artee Luchman, Research Assistant Professor, from the University of Calgary.

The new therapy is used to inhibit a pathway in the cancer cells known as mTOR signaling and, combined with the current standard therapy, caused more of the cancer cells to die.

Researchers used the new therapy to inhibit a pathway in the cancer cells known as mTOR signaling – putting the brakes on this pathway, combined with the current standard therapy, caused more of the cancer cells to die. Scientists are now working with investigators at the NCIC Clinical Trials Group (NCIC-CTG) to start a Canadian clinical trial that may eventually include glioblastoma patients across the country.

"Discovering new pathways and therapies that can be tested in the clinic provides the greatest hope for brain cancer patients and their families."

- Samuel Weiss, PhD, Professor and Director of the HBI

Phase 2 clinical trials will begin as early as next spring.

With researchers hoping that this treatment will become standard practice for glioblastoma patients, in the near future, your return on investment is the most powerful one we can imagine: more moments for Albertans facing cancer. Thank you for making investments that matter.

Photo credit Riley Brandt

Glioblastoma is the most common and deadly form of brain cancer among adults.

The median survival for patients is 15 months, with less than five per cent of patients surviving beyond five years.

AZD8055, when combined with Temozolomide (TMZ), could extended the life of patients by 30 percent.

View Our Other Progress Reports To Learn More About Impactful Investments

Spring 2017

Patient Navigators
Glioma
Patient Partnership
Breast Cancer

Spring 2016

Prostate Cancer
Head and Neck
Lymphoma
Patient Financial Assistance

Summer 2015

Art and Medicine
Patient Financial Assistance
Head and Neck Cancer
Immunotherapy 

Spring 2015

Clinical Trials Website
Patient Navigators
Screening for Distress
Tomorrow Project

Winter 2014

Mind and Body
Clinical Trials
Glioblastoma
We Will Help Video

Make an Investment Today


General Donation

 

Cancer Centres

Investment Priorities

Events

Giving in Memory

Other Ways to Give

  • RSS
  • Facebook
  • Twitter
  • YouTube
  • Instagram

Web design by Guide Creative